Drug news
NICE recommends Tarceva (Roche) for NSCLC
NICE has announced that Tarceva (erlotinib) from Roche will join Iressa (geftinib) from AstraZeneca in the UK and Wales as a first line option for patients with locally advanced or metastatic EFGR mutation positive Non Small Cell Lung Cancer.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.